[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:marginal-zone-lymphoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":310,"states":318},"Marginal Zone Lymphoma",61,53,[8,16,22,29,35,41,47,53,59,66,72,78,84,90,97,103,109,115,121,127,133,139,144,150,156,162,168,174,180,186,192,198,204,209,215,221,227,233,239,245,251,256,261,267,273,279,285,292,298,304],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06563505","A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed\u002FRefractory Marginal Zone Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:18:39.640967Z","2026-07-30T01:46:14.469172Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06350318","Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas",[12],"2026-08-26T02:17:56.243868Z","2026-05-05T02:43:29.381547Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT06149286","A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma",[26],"Phase 3","2026-08-26T02:19:19.162260Z","2026-05-05T02:43:29.214083Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT07029217","A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas",[26],"2026-08-26T02:16:31.714843Z","2026-05-05T02:43:28.883520Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06390956","Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)",[12],"2026-08-26T02:19:06.150683Z","2026-05-05T02:43:28.649739Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05296070","Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed\u002FRefractory Marginal Zone Lymphoma",[12],"2026-08-26T02:18:26.129155Z","2026-05-05T02:43:28.533465Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06792825","HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",[12],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:28.357811Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06563596","Epco, Zanu, Ritux for R\u002FR FL or MZL",[12],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:28.189974Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":64,"content_modified":65},"NCT04669171","A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma",[63],"Phase 1\u002FPhase 2","2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.101658Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06510309","Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma",[12],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:27.943364Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT05929612","A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma",[12],"2026-08-26T02:17:05.172421Z","2026-05-05T02:43:26.687913Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06442475","Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma",[12],"2026-08-26T02:17:01.714035Z","2026-04-29T02:57:57.111905Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL",[63],"2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.721924Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":95,"content_modified":96},"NCT05370430","BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL",[94],"Phase 1","2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.804231Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT04792502","Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma",[12],"2026-08-26T02:15:03.757872Z","2026-04-29T02:57:57.106355Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":107,"content_modified":108},"NCT05006716","A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies",[63],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.799692Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )",[94],"2026-08-26T02:15:54.846520Z","2026-07-05T05:32:16.733199Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT04545762","Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma",[94],"2026-08-26T02:18:03.638950Z","2026-07-05T03:45:20.448716Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT06484920","A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL",[12],"2026-08-26T02:15:31.806698Z","2026-05-05T02:43:29.397408Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT06708897","A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas",[94],"2026-08-26T02:17:57.117858Z","2026-05-05T02:43:29.367440Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[94],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.192735Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":131,"content_modified":143},"NCT07121946","This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma",[94],"2026-05-05T02:43:28.821913Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT04491370","Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma",[63],"2026-08-26T02:17:50.500039Z","2026-05-05T02:43:28.622855Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT04883437","Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas",[12],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:28.560079Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06590961","UBX-303061 in Subjects With Relapsed\u002FRefractory B-Cell Malignancies",[94],"2026-08-26T02:16:15.345907Z","2026-05-05T02:43:28.529005Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT06667687","Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma",[94],"2026-08-03T03:43:00.111924Z","2026-05-05T02:43:28.358180Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":172,"content_modified":173},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[12],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.206546Z",{"nct_id":175,"title":176,"phases":177,"status":13,"updated_at":178,"content_modified":179},"NCT06191887","B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies",[94],"2026-08-26T02:18:48.678868Z","2026-05-05T02:43:28.173828Z",{"nct_id":181,"title":182,"phases":183,"status":13,"updated_at":184,"content_modified":185},"NCT04728893","Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)",[12],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:28.133797Z",{"nct_id":187,"title":188,"phases":189,"status":13,"updated_at":190,"content_modified":191},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[12],"2026-08-26T02:17:29.353236Z","2026-05-05T02:43:28.075410Z",{"nct_id":193,"title":194,"phases":195,"status":13,"updated_at":196,"content_modified":197},"NCT04186520","CAR-20\u002F19-T Cells in Patients With Relapsed Refractory B Cell Malignancies",[63],"2026-08-26T02:15:44.309045Z","2026-05-05T02:43:27.998949Z",{"nct_id":199,"title":200,"phases":201,"status":13,"updated_at":202,"content_modified":203},"NCT06026319","CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma",[94],"2026-08-26T02:17:30.145302Z","2026-05-05T02:43:27.943297Z",{"nct_id":205,"title":206,"phases":207,"status":13,"updated_at":45,"content_modified":208},"NCT06340737","AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w\u002FRecurrent\u002FRefractory B Cell Lymphomas",[94],"2026-05-05T02:43:27.925479Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT04775745","Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.",[94],"2026-08-26T02:15:20.225313Z","2026-05-05T02:43:27.754680Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT04195633","Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",[12],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.479357Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT06533579","Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)",[63],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:27.324190Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT06879340","Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies",[94],"2026-08-26T02:16:50.548894Z","2026-05-05T02:43:27.323625Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT07424833","A Study of APG-3288 in Relapsed\u002FRefractory Blood Cancers",[94],"2026-08-26T02:16:34.792807Z","2026-05-05T02:43:27.286009Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[94],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":249,"content_modified":250},"NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[94],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:26.916657Z",{"nct_id":252,"title":253,"phases":254,"status":13,"updated_at":178,"content_modified":255},"NCT05780034","A Study of AC676 for the Treatment of Relapsed\u002FRefractory B-Cell Malignancies",[94],"2026-05-05T02:43:26.739406Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":70,"content_modified":260},"NCT05643742","A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies",[63],"2026-05-05T02:43:26.685166Z",{"nct_id":262,"title":263,"phases":264,"status":13,"updated_at":265,"content_modified":266},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[94],"2026-08-26T02:19:30.857183Z","2026-05-05T02:35:31.752653Z",{"nct_id":268,"title":269,"phases":270,"status":13,"updated_at":271,"content_modified":272},"NCT05602363","AS-1763 in Patients With Previously Treated CLL\u002FSLL or Non-Hodgkin Lymphoma",[94],"2026-08-26T02:17:36.611194Z","2026-05-05T02:35:31.742591Z",{"nct_id":274,"title":275,"phases":276,"status":13,"updated_at":277,"content_modified":278},"NCT05281809","Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia",[12],"2026-08-26T02:19:03.581490Z","2026-04-29T02:57:57.140676Z",{"nct_id":280,"title":281,"phases":282,"status":13,"updated_at":283,"content_modified":284},"NCT06859008","Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",[94],"2026-08-26T02:18:36.226508Z","2026-04-29T02:57:57.083288Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":290,"content_modified":291},"NCT06636175","64Cu-LLP2A for Imaging Hematologic Malignancies",[289],"Early Phase 1","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:28.740573Z",{"nct_id":293,"title":294,"phases":295,"status":13,"updated_at":296,"content_modified":297},"NCT07691606","A Study of ARC-02 in B-cell NHL",[94],"2026-08-26T02:18:42.501841Z","2026-07-19T19:36:05.152398Z",{"nct_id":299,"title":300,"phases":301,"status":13,"updated_at":302,"content_modified":303},"NCT07439653","A Study of TORL-5-700 in Relapsed\u002FRefractory Non Hodgkin's Lymphoma",[63],"2026-08-26T02:19:07.104270Z","2026-06-14T18:39:22.242932Z",{"nct_id":305,"title":306,"phases":307,"status":13,"updated_at":308,"content_modified":309},"NCT06151730","Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study",[],"2026-08-26T02:15:10.362237Z","2026-05-13T02:55:06.420129Z",[311,315],{"biomarker":312,"count":313,"slug":314},"CD19 Gene",5,"cd19-gene",{"biomarker":316,"count":313,"slug":317},"MS4A1 Gene","ms4a1-gene",[319,323,327,331,335,338,342,346,349,353,356,360,363,367,370,373,377,380,383,386,389,392,395,398],{"state":320,"count":321,"slug":322},"California",22,"california",{"state":324,"count":325,"slug":326},"Texas",19,"texas",{"state":328,"count":329,"slug":330},"New York",15,"new-york",{"state":332,"count":333,"slug":334},"Florida",13,"florida",{"state":336,"count":333,"slug":337},"Ohio","ohio",{"state":339,"count":340,"slug":341},"Washington",12,"washington",{"state":343,"count":344,"slug":345},"Minnesota",11,"minnesota",{"state":347,"count":344,"slug":348},"North Carolina","north-carolina",{"state":350,"count":351,"slug":352},"Tennessee",9,"tennessee",{"state":354,"count":351,"slug":355},"Utah","utah",{"state":357,"count":358,"slug":359},"Massachusetts",8,"massachusetts",{"state":361,"count":358,"slug":362},"Wisconsin","wisconsin",{"state":364,"count":365,"slug":366},"Colorado",7,"colorado",{"state":368,"count":365,"slug":369},"Georgia","georgia",{"state":371,"count":365,"slug":372},"Maryland","maryland",{"state":374,"count":375,"slug":376},"Illinois",6,"illinois",{"state":378,"count":375,"slug":379},"Kentucky","kentucky",{"state":381,"count":375,"slug":382},"Michigan","michigan",{"state":384,"count":375,"slug":385},"New Jersey","new-jersey",{"state":387,"count":313,"slug":388},"Iowa","iowa",{"state":390,"count":313,"slug":391},"Kansas","kansas",{"state":393,"count":313,"slug":394},"Missouri","missouri",{"state":396,"count":313,"slug":397},"Pennsylvania","pennsylvania",{"state":399,"count":400,"slug":401},"Indiana",4,"indiana"]